A Comprehensive Exploration of the Biological Effects of Adipose-Derived Stem Cells in the Treatment of Systemic Sclerosis
- PMID: 40136706
- PMCID: PMC11941144
- DOI: 10.3390/cells14060458
A Comprehensive Exploration of the Biological Effects of Adipose-Derived Stem Cells in the Treatment of Systemic Sclerosis
Abstract
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vasculopathy and tissue fibrosis affecting the skin and internal organs. Genetic and environmental factors influence susceptibility, severity, and onset. Current treatments are limited and not always effective, leading researchers to investigate new approaches, such as the use of adipose-derived mesenchymal stem cells (ADSCs) through fat grafting. This review seeks to understand how ADSCs may impact the development and progression of SSc, with a particular focus on how these cells could alter immune responses and reduce fibrosis. ADSCs have been found to affect various immune cells, including T cells, B cells, macrophages, and dendritic cells, by releasing cytokines, chemokines, and growth factors. These interactions generally suppress inflammation and promote a regulatory immune environment. Additionally, ADSCs can influence the extracellular matrix, helping to prevent fibrosis through signaling molecules like exosomes. ADSCs show promise as a treatment for SSc due to their ability to modulate the immune system and reduce fibrosis. Early clinical studies are encouraging, but more research is needed to fully understand how they work and to develop effective treatment protocols.
Keywords: ADSC; lipofilling; systemic sclerosis.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Exosomes carrying adipose mesenchymal stem cells function alleviate scleroderma skin fibrosis by inhibiting the TGF-β1/Smad3 axis.Sci Rep. 2025 Feb 28;15(1):7162. doi: 10.1038/s41598-024-72630-6. Sci Rep. 2025. PMID: 40021656 Free PMC article.
-
Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients.Stem Cell Res Ther. 2017 Oct 23;8(1):236. doi: 10.1186/s13287-017-0690-3. Stem Cell Res Ther. 2017. PMID: 29058626 Free PMC article.
-
Resistin promotes cardiac homing of mesenchymal stem cells and functional recovery after myocardial ischemia-reperfusion via the ERK1/2-MMP-9 pathway.Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H233-H244. doi: 10.1152/ajpheart.00457.2018. Epub 2018 Nov 9. Am J Physiol Heart Circ Physiol. 2019. PMID: 30412442
-
Mesenchymal stromal cells for systemic sclerosis treatment.Autoimmun Rev. 2021 Mar;20(3):102755. doi: 10.1016/j.autrev.2021.102755. Epub 2021 Jan 18. Autoimmun Rev. 2021. PMID: 33476823 Review.
-
Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease.Stem Cell Res Ther. 2023 Dec 18;14(1):372. doi: 10.1186/s13287-023-03543-w. Stem Cell Res Ther. 2023. PMID: 38111001 Free PMC article. Review.
References
-
- Storti G., Scioli M.G., Kim B.-S., Terriaca S., Fiorelli E., Orlandi A., Cervelli V. Mesenchymal Stem Cells in Adipose Tissue and Extracellular Vesicles in Ovarian Cancer Patients: A Bridge toward Metastatic Diffusion or a New Therapeutic Opportunity? Cells. 2021;10:2117. doi: 10.3390/cells10082117. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical